US Patent 10,550,081 Landscape: Scope, Claim Boundaries, and US Exclusivity Risk for Crystalline Freebase of Biphenyl-2-ylcarbamic Acid Ester
US Patent 10,550,081 is claim-limited to a specific crystalline “freebase” form and its DSC fingerprint, plus corresponding pharmaceutical compositions. The practical scope is narrow: it tracks a single chemical entity (the named biphenyl-2-ylcarbamic acid ester) in a defined crystalline solid state with an asserted melting point near 125°C and, in parallel, a DSC thermogram “in accordance with” FIG. 4. The enforceable moat is therefore the solid-state characterization (crystal form) rather than broad chemical genus coverage.
What does US Patent 10,550,081 claim, and how narrow is the scope?
Short answer: It claims (i) a crystalline freebase of a precisely defined active (structure specified in the claim), (ii) the same crystalline freebase identified by a DSC thermogram matching FIG. 4, and (iii) pharmaceutical compositions containing that crystalline freebase (carrier + API), again tied to the same melting point and/or DSC signature.
Claim-set overview (as provided)
From the claim text supplied:
-
Claim 1: Crystalline freebase of
biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester
melting point about 125°C.
-
Claim 2: Same crystalline freebase, defined by DSC thermogram “in accordance with that shown in FIG. 4.”
-
Claim 3: Pharmaceutical composition = pharmaceutically acceptable carrier + crystalline freebase of the above API with melting point about 125°C.
-
Claim 4: Pharmaceutical composition = carrier + crystalline freebase of the above API with DSC thermogram in accordance with FIG. 4.
What the claim language effectively limits
- Form limitation dominates. “Crystalline freebase” plus a measured melting point and/or DSC fingerprint creates a solid-state limitation. This is not a salt form claim, not a polymorph-agnostic claim, and not an amorphous claim.
- Product-by-solid-state characterization. Claims 2 and 4 are “analytical-defined” (DSC thermogram matching FIG. 4). That usually narrows the “covered substance” to the same or substantially equivalent thermal behavior.
- Composition claim is basic. Claims 3 and 4 do not add formulation-specific constraints (no dose, no excipient selection, no particle size, no solid dispersion, no route). They cover any composition where the API is the claimed crystalline freebase.
- No broad method-of-treatment coverage is present in the provided claims. The provided claim set is product/solid-state focused.
How does the melting point “about 125°C” constraint affect infringement?
Short answer: “About 125°C” introduces a tolerance band, but it still functions as a gatekeeper. A different crystal form that melts outside the tolerance may avoid Claim 1 and Claim 3, even if it is chemically identical to the freebase.
Practical scope boundaries created by “about”
- Measurement dependence: Melting point is sensitive to sample prep (drying history, polymorph content), heating rate, instrument, and hermeticity.
- Tolerance is not quantified in the claim text you provided. Still, enforcement will typically treat “about” as a range around 125°C and expect reproducibility.
- Common design-around: If a competitor can obtain a crystalline form with a melting point outside the expected tolerance band, Claim 1/3 are at risk of non-infringement on thermal criteria.
Claim relationship: Claim 1 vs Claim 2
- If a competitor’s form has melting point outside the “about 125°C” range, but the DSC thermogram matches FIG. 4, Claim 2/4 remain a potential target.
- If DSC does not match FIG. 4, matching melting point alone may not secure infringement for Claim 2/4.
How strong is the DSC thermogram “in accordance with FIG. 4” limitation?
Short answer: DSC-matching claims can be powerful in litigation because they are tied to specific experimental signatures, but they also invite expert battle over what “in accordance with” means and whether test conditions make the spectra “match.”
Why this matters for infringement
- FIG. 4 is a specific reference. The claim imports the reference thermogram into the legal definition.
- “In accordance with” is functional but testable. It suggests that the claimed DSC thermogram must look like the reference. In practice, the dispute becomes whether the accused material’s DSC trace is sufficiently similar to FIG. 4 under comparable conditions.
Typical factors that become battlegrounds (for DSC-defined claims)
- DSC protocol and normalization (baseline correction, heating rate, sample mass).
- Drying and residual solvent content.
- Polymorph mixtures (partial transformation during heating).
- Instrument-to-instrument variance and statistical similarity thresholds.
Infringement strategy consequences
- If your material is the same crystalline form: DSC will likely match, keeping Claim 2/4 in play.
- If your material is a different polymorph/solvate/individual crystal form: DSC may diverge even if melting point is similar.
What chemical entity is protected: is the patent about the API or the solid state?
Short answer: The claims require both. They specify a particular chemical structure by name in the claim, then require a particular crystalline freebase form characterized by melting point and DSC.
How to read the structure string
The claimed freebase is:
- biphenyl-2-ylcarbamic acid
- esterified at “1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl”
This means the patent is not claiming a generic “biphenyl-2-ylcarbamic acid freebase.” It claims the specific ester. The identity of the structure is a threshold. Any attempt to use a different chemical entity avoids the claim at the API-identity level even if solid-state matches.
Which pharmaceuticals would fall under the composition claims (Claims 3 and 4)?
Short answer: Any pharmaceutical composition with a pharmaceutically acceptable carrier that contains the claimed crystalline freebase, regardless of excipient identity, as long as the API’s solid form criteria are met.
Composition claim coverage
- Carrier is open-ended. “Pharmaceutically acceptable carrier” does not limit to oral tablets, capsules, injectables, etc.
- No formulation limits appear in the claim text supplied. That makes Claims 3/4 potentially broader than many formulation patents, though still constrained by the claimed solid-state identity.
The key infringement trigger for composition claims
Even if the dosage form is different (tablet vs capsule vs suspension), Claims 3/4 can still apply if the crystalline freebase included in the formulation meets:
- melting point about 125°C (Claim 3), and/or
- DSC thermogram consistent with FIG. 4 (Claim 4).
How can a generic or competitor design around this patent?
Short answer: The most credible design-around is solid-state switching (different polymorph) or solid-state processing that changes thermal/DSC profiles, while maintaining the same API structure but avoiding the specific crystalline freebase defined by the patent.
Design-around pathways aligned to claim structure
-
Different crystalline form with different melting point
- Aim: move melting point outside the tolerated range around 125°C.
- Risk: DSC mismatch may still protect against Claim 2/4, but if DSC matches, Claim 2/4 can still be implicated.
-
Same melting behavior but different DSC pattern
- Aim: avoid “in accordance with FIG. 4.”
- Risk: if thermal peaks coincide closely, DSC-based infringement risk rises.
-
Amorphous or non-crystalline material
- Aim: avoid “crystalline freebase.”
- Risk: if a material crystallizes during manufacturing or storage, it may become a crystalline freebase and re-enter scope.
-
Salt forms instead of freebase
- Aim: avoid “freebase.”
- Risk: if the marketed product effectively uses the freebase (or converts), claim risk rises.
Practical point for FTO
Because the claims require crystalline freebase and specific thermal characterization, an FTO analysis must treat solid-state evidence as central, not peripheral.
What is the patent estate relevance: is this a primary or ancillary IP layer?
Short answer: Based on the claim types you provided, US 10,550,081 is an IP layer focused on a particular crystalline freebase form. In most small-molecule portfolios, this is usually an “incremental” patent layer that becomes important when earlier patents cover the chemical entity but have expired or are nearing expiration.
Typical estate architecture for crystalline form patents
- Core composition/compound patents: often earlier, broader.
- Crystal/polymorph/solid form patents: later, narrower, sometimes used to extend exclusivity.
- Formulation patents: later again, but can be broad or narrow depending on excipient/dose constraints.
- Method-of-use patents: orthogonal coverage.
Your provided claims show no method-of-use language and no broad composition limits beyond the solid-state. That pattern is consistent with a solid-form extension.
What Orange Book status questions matter for this patent, and what is the likely Orange Book role?
Short answer: Whether US 10,550,081 appears in the Orange Book depends on the NDA/BLA and whether FDA listing ties that crystalline form to the marketed drug product. If it is listed for an approved drug, it can block generic approval via Paragraph IV or trigger carve-outs based on different polymorphs.
Limits of this analysis: The claim text you provided does not identify the NDA number, listed product, or the approved dosage forms. Without that, Orange Book status cannot be mapped to a specific NDA listing or listed drug.
How do Paragraph IV certifications and generic launch scenarios interact with crystalline-form claims?
Short answer: Crystalline-form patents create generic launch risk that hinges on whether the ANDA’s manufactured API matches the patented solid form. A successful ANDA can still face infringement if it uses the same crystalline freebase.
Scenario taxonomy (infringement-focused)
- ANDA uses the claimed crystalline form: likely high infringement risk for Claims 1-4.
- ANDA uses a different polymorph but same chemical entity: risk shifts to whether DSC and melting-point criteria still match.
- ANDA uses amorphous material or a different salt: reduced risk if “freebase crystalline” is avoided and conversion is controlled.
What litigation arguments are likely with DSC- and melting-point-defined crystalline claims?
Short answer: Disputes will center on whether the accused material is the same crystalline freebase and whether test conditions produce DSC traces “in accordance with FIG. 4,” plus enforceability issues typical for solid-state form claims.
Common dispute themes for crystalline form patents
- Is the accused API crystalline freebase or a different form?
- Does the accused material meet “melting point about 125°C”?
- Does its DSC trace match FIG. 4 under comparable conditions?
- Claim construction: how strictly “in accordance with” is construed.
- Evidentiary repeatability: whether different lots and labs reproduce the same thermal profiles.
What prior art categories usually attack crystalline freebase claims?
Short answer: Crystalline form patents often face obviousness/anticipation attacks using earlier disclosures that:
- show the same crystal form,
- disclose equivalent polymorphs with overlapping thermal behavior,
- or teach methods to crystallize the freebase without recognizing the specific DSC signature.
Limits of this analysis: No file history, specification content, citations, or cited references were provided with the request. A full prior-art mapping cannot be produced from claim text alone.
Key Takeaways
- Scope is narrow and solid-state driven: US 10,550,081 is limited to a specific crystalline freebase of a defined biphenyl-2-ylcarbamic acid ester, with inclusion tied to melting point about 125°C and/or DSC thermogram matching FIG. 4.
- Claims 1/3 hinge on thermal threshold; claims 2/4 hinge on DSC identity. Non-overlap on either metric can be a viable non-infringement route.
- Composition coverage is broad in formulation terms but narrow in API form terms: any dosage form can fall in if the carrier contains the claimed crystalline freebase and satisfies the solid-state characterization.
- FTO and generic risk are manufacturing-dependent: the decisive question is what crystalline form is produced, tested, and persists in the ANDA product.
FAQs
1) Can an accused product avoid infringement by changing excipients while keeping the same crystalline freebase?
Excipients alone do not avoid infringement if the API remains the claimed crystalline freebase meeting the melting-point and/or DSC criteria.
2) If a competitor’s API melts near 125°C but has a different DSC profile, which claims are most at risk?
Claim 1/3 risk increases if melting point fits; Claim 2/4 risk increases only if the DSC trace is “in accordance with FIG. 4.”
3) Does Claim 2 require an exact match to FIG. 4 or a close similarity?
The claim text ties the thermogram to FIG. 4, making similarity a central issue for claim construction and expert comparison under the DSC protocol.
4) Can a different polymorph still be a “crystalline freebase” that infringes?
It depends whether the different polymorph still satisfies the claim characterization tests (melting point and/or DSC alignment to FIG. 4).
5) Are method-of-use or dosing regimens covered by this patent based on the claim text provided?
No method-of-use dosing regimen claims are present in the supplied claim set; the claims are product and composition focused on the crystalline freebase.
References
- US Patent 10,550,081.
